- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01070394
Effectiveness and Duration of Effect of Open Treatment in Attention Deficit Hyperactivity Disorder (ADHD) Patients Treated With Lisdexamfetamine Dimesylate(Vyvanse)
Evaluation of Pharmacokinetics and Profile of Clinical Response of Subacute Lisdexamfetamine Dimesylate (Vyvanse) Treatment vs. Clinical Response to Subacute Immediate Release Mixed Amphetamine Salt Therapy in Adult ADHD
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Protocol Summary:
Effectiveness and Duration of Effect of Open Treatment in Adult ADHD Patients Treated with Lisdexamfetamine Dimesylate- LDX (Vyvanse)
The primary objective of this study is to evaluate the effectiveness and duration of effect of LDX for the treatment of ADHD symptoms in adults. The study will be a 12-week open label extension with 25 adult participants who completed a cross-over study of adherence/efficacy of Adderall Immediate Release (IR) vs. Adderall Extended Release (XR).
The secondary objective is to provide information regarding tolerability, dosing and titration of LDX in the adult population with ADHD.
An additional fifteen participants will be recruited using advertising and previous Mental Health and Addictive Behaviour Research Program (MHADRP) studies will be offered treatment with LDX. All participants will be diagnosed with ADHD using the Adult Clinician Diagnostic Scale (ACDS). We will be collecting demographic information, administering the Scheduled Clinical Interview for DSM Disorders (SCID), collecting medical history, previous drug therapy, and the participant will have a physical with the physician. A coordinator will give an electrocardiogram (ECG), and collect a blood sample for blood chemistry and hematology.
Schedule of Events: Vyvanse Extension Screening Visit
- Consent
- Demographics (needs to be added?)
- Physical
- Medical history (needs to be added?)
- Previous drug therapy
- Vitals (Blood Pressure-BP, Heart Rate-HR, Respiration, weight)
- Urine Drug screen
- Urine pregnancy test
- ECG
- Blood sample
- SCID
- ACDS
Visits at week 0,1,2,3,4,6,8,10,12 (every visit)
- ADHD-Rating Scale (ADHD-RS)
- Adult ADHD Self-Report Scale (ASRS)
- Clinical Global Impression (CGI)
- Vitals
- Pill count
- Adverse Events (AE)/ Concomitant Medications (CM)
Visits at week 0,1,4,6,12 also administer
- Adult ADHD Medication Rebound Scale (AMRS) (AM/PM)
- Adult ADHD Medication Smoothness of Effect Scale (AMSES) (AM/PM)
- Wender-Reimherr Adult Attention Deficit Disorder Scale (WRAADS) (AM/PM)
First 4 weeks of treatment is a dose adjustment period (30-70 mg po qAM), after those 4 weeks established dose is remained for remaining 8 weeks of treatment.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10016
- NYU School of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- At the time of consent, are between the ages of 18-55, inclusive.
- Meet DSM-IV criteria for ADHD as assessed by the Adult ADHD Clinician Diagnostic Scale (ACDS) v1.2.
- Female participants of childbearing potential must test negative for pregnancy at the time of enrollment based on a urine pregnancy test and agree to use a reliable method of birth control during the study. Females of childbearing potential are defined as women not surgically sterilized and are between menarche and 2 years post-menopause.
- Must have a satisfactory medical assessment with no clinically significant abnormalities as determined by medical history, physical exam, ECG, and clinical laboratory testing.
- Must be able to swallow capsules.
- Must be able to begin the daily dose of study medication in the morning.
- Must be off all ADHD therapies for one week (psychostimulants) and three weeks (non-stimulants).
- In the opinion of the investigator, the subject must understand and be able, willing and likely to fully comply with the study procedures and restrictions.
- Must have given signed and dated informed consent in accordance with Good Clinical Practice (GCP) Guidelines.
Exclusion Criteria:
- Participants with a positive urine drug result at Screening.
- Anyone who meets current DSM-IV-TR criteria for alcohol or any non-alcohol substance abuse or dependence disorder (excluding nicotine).
- Participants with controlled depressive or anxiety disorders may not participate if, in the opinion of the Principal Investigator, their medications will interfere with safety or efficacy assessments.
- Participants with any concurrent chronic or acute illness or unstable medical condition that could, in the opinion of the study physician, confound the results of safety assessments, increase risk to the subject or lead to difficulty complying with the protocol.
- Participants with hypertension at screening, indicated by a blood pressure reading of 135/90 and heart rate above 120bmp.
- Female participants of childbearing potential who test positive for pregnancy at the time of enrollment based on a urine pregnancy test, or who do not agree to use a reliable method of birth control during the study. Females of childbearing potential are defined as women not surgically sterilized and are between menarche and 2 years post-menopause.
- Participants who work the night shift or another schedule that would preclude beginning the daily dose of study medication in the morning.
- Participants who in the investigator's opinion meet any of the exclusionary criteria specified on the FDA label of Vyvanse.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: LDX Treatment
Eligible participants received 12 weeks of open-label treatment.
Those on treatment prior to baseline underwent a 7-day (for amphetamine or methylphenidate) or 28-day (for atomoxetine or other medications) washout period prior to initiating LDX treatment.
The starting dose was 30mg/day, which could be titrated up by 20mg/day during visits 2-6 (for a maximum dose of 70mg/day).
At discretion of investigator, the dose could be down-titrated by 20mg/day during visits 4-6.
Once the dose was optimized (after visit 6), the dose was maintained for 8 weeks.
|
30 mg, 50mg, or 70 mg.
Oral capsule, once a day, for 12 weeks.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Attention Deficit Hyperactivity Disorder- Rating Scale (ADHS-RS)
Time Frame: 12 weeks
|
The ADHD-RS with adult ADHD prompts is a semi-structured scale that consists of 18 items that directly correspond to the 18 DSM-IV symptoms of ADHD, and is designed to assess current symptomatology19. Each item is scored on a 4-point scale ranging from 0 (none) to 3 (severe).Each item on the 18-item measure is scored on a 4-point scale ranging from 0 (no symptoms) to 3 (severe symptoms), yielding a possible total score of 0-54. A score of 0-16 means "Unlikely to have ADHD"; a score of 17-23 "Likely to Have ADHD" ; 24 or greater-Highly Likely to have ADHD |
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Symptom Rebound Score Using the Adult ADHD Medication Rebound Scale (AMRS).
Time Frame: Week 0 to Week 12
|
To evaluate the symptom rebound throughout a single day (assessed via the AMRS) with LDX treatment.
Scoring on the AMRS based on 38 items, each scored 0 (None), 1 (Mild), 2 (Moderate), 3 (Severe).
The lowest scored units on a scale for 1 individual is 0, the highest 114.
The scores reported below are Mean scores for 33 patients analyzed.
|
Week 0 to Week 12
|
Change in Measure of Smoothness of Effect Using Adult ADHD Medications Smoothness of Effect Scale (AMSES)
Time Frame: Visits 0 and 12
|
The Adult ADHD Medication Smoothness of Effect Scale (AMSES) is a 6-item, frequency-based, self-report scale that was recently developed to assess the consistency and duration of effect of ADHD medication throughout the day.
The AMSES compares the effectiveness of ADHD medication shortly after dosing with the effectiveness later in the day.
Respondents are asked to rate how frequently the effective-ness of their medication was the same 2 hr post-dose as it was 4, 6, 8, 10, and 12 hr post-dose on a 0 to 4 scale (0 = never, 1 = rarel, 2 = sometimes, 3 = often, 4 = very often).
In addition, respondents rate how frequently the delivery of their medication was consistent and smooth throughout the day on a visual analog scale ranging from 0 (never) to 100 (very often).
|
Visits 0 and 12
|
Correlation Between AMRS (In Clinic) and ADHD-RS
Time Frame: Visits 0 and 12
|
To correlate symptom rebound through a single day (assessed via the AMRS) with a global (ADHD-RS) measure of efficacy of LDX treatment.
AMRS and ADHD-RD scores obtained on Day 0 and Day 12 will be correlated.
The Pearson's correlation coefficients for the In-Clinic assessment will be presented for Visits 0 and 12.
|
Visits 0 and 12
|
Change in Correlation Between AMRS and TASS
Time Frame: Visits 0 and 12
|
To correlate symptom rebound through a single day (assessed via the AMRS) with a time-sensitive (TASS) measure of efficacy of LDX treatment.
A Pearson's correlation coefficient will be presented.
AMRS and TASS scores obtained on Day 0 and Day 12 will be correlated.
The Pearson's correlation coefficients for the In-Clinic assessment will be presented for Visits 0 and 12.
|
Visits 0 and 12
|
Correlation Between In-Clinic AMRS and ASRS v.1.1 Symptom Checklist
Time Frame: Baseline to Week 12
|
To correlate symptom rebound through a single day (assessed via the AMRS) with a self assessment of ADHD Symptoms.
A Pearson's correlation coefficient will be presented.
AMRS and self assessment of ADHD scores obtained on Day 0 and Day 12 will be correlated.
The Pearson's correlation coefficients for the In-Clinic assessment will be presented for Visits 0 and 12.
|
Baseline to Week 12
|
Psychometric Validation of AMRS
Time Frame: Weeks 0-12
|
To perform secondary psychometric validations of the AMRS using Cronbach's alpha coefficients.
|
Weeks 0-12
|
Psychometric Validation of AMSES
Time Frame: Weeks 0-12
|
To perform secondary psychometric validations of the AMSES using Cronbach's alpha coefficients.
|
Weeks 0-12
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
General Publications
- Adler LA, Alperin S, Leon T, Faraone S. Clinical effects of lisdexamfetamine and mixed amphetamine salts immediate release in adult ADHD: results of a crossover design clinical trial. Postgrad Med. 2014 Sep;126(5):17-24. doi: 10.3810/pgm.2014.09.2796.
- Mattingly GW, Weisler RH, Young J, Adeyi B, Dirks B, Babcock T, Lasser R, Scheckner B, Goodman DW. Clinical response and symptomatic remission in short- and long-term trials of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. BMC Psychiatry. 2013 Jan 29;13:39. doi: 10.1186/1471-244X-13-39.
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Nervous System Diseases
- Neurologic Manifestations
- Dyskinesias
- Attention Deficit and Disruptive Behavior Disorders
- Neurodevelopmental Disorders
- Attention Deficit Disorder with Hyperactivity
- Hyperkinesis
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Dopamine Agents
- Dopamine Uptake Inhibitors
- Central Nervous System Stimulants
- Lisdexamfetamine Dimesylate
Other Study ID Numbers
- 10-00510
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Attention Deficit Hyperactivity Disorder
-
Cingulate TherapeuticsRecruitingPhase 3 Efficacy and Safety Laboratory Classroom Study in Pediatrics (6-12) With ADHD Using CTx-1301ADHD | Attention Deficit Hyperactivity Disorder | Attention Deficit Disorder With Hyperactivity | ADHD - Combined Type | Attention Deficit Hyperactivity Disorder Combined | Attention Deficit Hyper Activity | Attention-deficit HyperactivityUnited States
-
Ornit CohenUnknownAttention Deficit Hyperactivity Disorder | Attention Deficit Disorder With Hyperactivity | Attention Deficit Disorder | Attention Deficit Disorders With Hyperactivity | Attention Deficit Hyperactivity DisordersIsrael
-
Cingulate TherapeuticsPremier Research Group plcActive, not recruitingADHD | Attention Deficit Hyperactivity Disorder | ADHD - Combined Type | Attention Deficit Hyperactivity Disorder Combined | Attention Deficit Hyper Activity | Attention-deficit HyperactivityUnited States
-
Children's National Research InstituteRecruitingADHD | Attention Deficit Hyperactivity Disorder | Attention-Deficit Hyperactivity Disorder | Attention Deficit Disorder | ADD | ADHD Predominantly Inattentive Type | ADHD - Combined Type | ADHD, Predominantly Hyperactive - Impulsive | Attention-Deficit Disorder in Adolescence | Attention-Deficit Hyperactivity...United States
-
Fondation LenvalCompletedAttention Deficit Disorder With Hyperactivity | Attention Deficit Disorder Without HyperactivityFrance
-
University Hospital Bispebjerg and FrederiksbergMental Health Services in the Capital Region, DenmarkRecruitingSleep Disturbance | Neurodevelopmental Disorders | Attention Deficit Hyperactivity Disorder | Attention Deficit Disorder | Attention-Deficit Hyperactivity Disorder, Unspecified Type | Attention-deficit Hyperactivity | Hyperkinetic Conduct DisorderDenmark
-
Corium, Inc.Worldwide Clinical Trials; Premier Research Group plc; Almac; Prometrika, LLCRecruitingAttention Deficit/Hyperactivity DisorderUnited States
-
Corium, Inc.Premier Research Group plc; Almac; Prometrika, LLCActive, not recruitingAttention Deficit/Hyperactivity DisorderUnited States
-
Massachusetts General HospitalShire Human Genetic Therapies, Inc.Active, not recruitingAttention Deficit/Hyperactivity DisorderUnited States
-
Ataturk UniversityCompletedAttention-deficit/Hyperactivity DisorderTurkey
Clinical Trials on LDX Treatment
-
Dompé Farmaceutici S.p.ACompleted
-
Dompé Farmaceutici S.p.ATerminatedNew-onset Type 1 DiabetesUnited States, Belgium, Georgia, Germany, Italy, Serbia
-
Dompé Farmaceutici S.p.ATerminated
-
Dompé Farmaceutici S.p.AWithdrawnType I DiabetesUnited States
-
Centre hospitalier de l'Université de Montréal...Canadian Institutes of Health Research (CIHR)RecruitingAddiction | Methamphetamine-dependence | Addiction, Substance | Methamphetamine AbuseCanada
-
ShireCompletedAttention Deficit Hyperactivity Disorder (ADHD)United States
-
ShireCompletedHealthyUnited States
-
ShireCompletedBinge Eating DisorderUnited States, Spain, Germany, Canada, Sweden
-
ShireCompleted